Comparison of thrice weekly vs daily human leucocyte interferon‐α therapy for chronic hepatitis C
- 1 July 1999
- journal article
- clinical trial
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 6 (4), 321-327
- https://doi.org/10.1046/j.1365-2893.1999.00165.x
Abstract
Standard treatment for chronic hepatitis C currently consists of 3–6 million units (MU) of interferon-α (IFN-α) given thrice weekly (t.i.w.) for 12 months, obtaining rates of sustained response (SR) that usually do not exceed 15–25%. Some recent reports have suggested that daily administration of IFN-α may be more efficacious. More than 7 years ago, when standard therapy for hepatitis C was usually given for 6 months, we conducted a randomized clinical trial comparing daily vs t.i.w. treatment. In this study, 149 patients with chronic hepatitis C were randomized to received 3 MU of IFN-α either t.i.w. for 6 months or daily for 3 months followed by t.i.w. for 3 months. All patients were treated with human leucocyte IFN-α and were followed-up for up to 72 months after inclusion. Overall, patients treated daily or t.i.w. had similar rates of virological response after 3 months of induction [24/49 (50%) vs 40/100 (40%)], at the end of therapy [15/49 (31%) vs 36/100 (36%)] and at the end of follow-up [6/49 (12%) vs 9/100 (9%)]. However, when patients infected with HCV types other than HCV-1 were studied, there was a trend favouring the daily schedule that was associated with a higher [5/20 (25%) vs 5/48 (10%)] rate of long-term SR. All patients with a virological response – hepatitis C virus (HCV) RNA negative in serum as determined using the polymerase chain reaction – at 6 months after therapy remained in biochemical and virological remission at long-term follow-up, while seven of eight subjects who had normal alanine aminotransferase (ALT) levels but were serum positive for HCV RNA at 6 months, relapsed later, indicating that serum HCV RNA is better than ALT at predicting long-term cure after IFN-α therapy in chronic hepatitis C.Keywords
This publication has 13 references indexed in Scilit:
- Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: Results of an international randomized controlled trialHepatology, 1998
- Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis CThe Lancet, 1998
- Therapy of hepatitis C: Meta-analysis of interferon alfa-2b trialsHepatology, 1997
- Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfaHepatology, 1997
- Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and durationHepatology, 1996
- Histological grading and staging of chronic hepatitisJournal of Hepatology, 1995
- Clinical Outcomes after Transfusion-Associated Hepatitis CNew England Journal of Medicine, 1995
- Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysisJournal of General Virology, 1994
- Long-Term Mortality after Transfusion-Associated Non-A, Non-B HepatitisNew England Journal of Medicine, 1992
- Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitisHepatology, 1991